Compare Novo Nordisk A/S (NVO) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tripadvisor Inc Common Stock — how do they compare? Novo Nordisk A/S trades at $46.23 (market cap $207.85B), while Tripadvisor Inc Common Stock trades at $10.59 (market cap $1.28B). The key difference: Novo Nordisk A/S is far larger — about 162.4× Tripadvisor Inc Common Stock's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| NVO | TRIP | |
|---|---|---|
Market Cap | $207.85B | $1.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $19.14 |
52-Week Low | $35.29 | $9.24 |
Enterprise Value | $222.55B | $1.33B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Tripadvisor (TRIP) trades at $10.59, down 1.76% on the day, with a bearish technical signal and recent earnings misses. The company reported Q2 2026 EPS of $0.35, below the $0.42 estimate (Zacks Investment Research, 2026-08-06). Revenue was $1.89B in 2025, with net income improving to $40M. Analyst consensus is a $13.29 price target, but sentiment is mixed with 62.5% hold ratings. The sale of TheFork for $700M provides cash but highlights competitive pressures from AI travel tools.
The outlook is cautious; while valuation ratios like P/S of 0.72 appear attractive, weak profitability and competitive threats from AI-driven platforms pose significant risks. Near-term catalysts include TheFork sale proceeds and Viator's performance, but investor sentiment remains neutral amid earnings volatility and macro headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
